The Indian Pharma Market (IPM) clocked Rs 6291 crores in November 2013. It has seen a growth at 6.9 per cent for November 2013. Macleods becomes the 10th biggest company in IPM versus 11th of last month. November 13 growth driver split shows positive on the parameter of volume and new introductions leading to overall positive growths over October 2012
Amongst the top 10, Sun Pharma at 17.1 per cent followed by Alkem at 12.5 per cent. 34 of the top 50 corporates have crossed the growth of IPM for November 2013. Amongst the top 50 corporates, Corona Remedies has the highest growth of 87.2 per cent followed by Biocon at 49.6 per cent and Ipca at 28.3 per cent. Glenmark has shown the highest growth at 25.6 per cent followed by Aristo at 20.8 per cent and USV at 20.6 per cent. Akumentis has entered the Rs 250 crore club, BMS the Rs 100 crore club. Amongst the top 50 in MNCs, AstraZeneca grew the highest at 20 per cent, followed by Allergan at 16.5 per cent and Merck at 12.1 per cent.
|
With Bonus Units at Full Value (Val in Crs)
|
||||||||
|
Rank
|
MAT Nov -13
|
Nov-13
|
||||||
|
COMPANY
|
MAT
|
MTH
|
Val (Cr)
|
MS%
|
GR%
|
Val (Cr)
|
MS%
|
GR%
|
| IPM |
72772
|
100.00
|
5.3
|
6291
|
100.00
|
6.9
|
||
| Sun Pharma |
1
|
1
|
3873
|
5.32
|
17.4
|
357
|
5.67
|
17.1
|
| Cipla |
2
|
2
|
3694
|
5.08
|
5.6
|
328
|
5.22
|
12.2
|
| Zydus Cadila |
3
|
3
|
2987
|
4.10
|
13.7
|
262
|
4.16
|
9.9
|
| Ranbaxy |
4
|
4
|
2916
|
4.01
|
2.1
|
251
|
3.98
|
2.1
|
| Glaxo |
5
|
7
|
2886
|
3.97
|
-10.5
|
221
|
3.51
|
-20.1
|
| Abbott HC |
6
|
5
|
2702
|
3.71
|
1.1
|
232
|
3.69
|
3.3
|
| Mankind |
7
|
6
|
2627
|
3.61
|
6.8
|
232
|
3.68
|
10.4
|
| Alkem |
8
|
8
|
2283
|
3.14
|
8.5
|
206
|
3.27
|
12.0
|
| Lupin |
9
|
9
|
2197
|
3.02
|
6.6
|
195
|
3.09
|
9.9
|
| Macleods |
10
|
10
|
1878
|
2.58
|
7.5
|
167
|
2.66
|
11.7
|
| Intas |
11
|
12
|
1853
|
2.55
|
12.9
|
160
|
2.54
|
12.0
|
| Aristo |
12
|
11
|
1736
|
2.39
|
7.2
|
166
|
2.63
|
20.8
|
| Pfizer |
13
|
16
|
1627
|
2.24
|
-1.3
|
124
|
1.97
|
-16.6
|
| Dr. Reddys |
14
|
14
|
1618
|
2.22
|
8.5
|
139
|
2.22
|
7.2
|
| Glenmark |
15
|
13
|
1543
|
2.12
|
15.0
|
146
|
2.31
|
25.6
|
| Abbott |
16
|
15
|
1419
|
1.95
|
3.6
|
125
|
1.98
|
10.7
|
The DPCO 2013 containing molecules market was at –8.6 per cent whereas the non-DPCO market grew by 9.5 per cent resulting in an overall growth of 6.9 per cent for November 2013. The DPCO 2013 portfolio for GSK de-grew at 31.8 per cent and Ranbaxy de-grew by 20.7 per cent, whereas Sun Pharma had the least impact with its DPCO 2013 portfolio de-growing at 6.8 per cent. The unit market grew positively after a long time.
From therapy perspective, eight therapies have outgrown the IPM growth. The gastrointestinal market grew at 8.4 per cent, anti-infective market had a growth of 2.6 per cent whereas respiratory market had a 15.1 per cent growth. The anti-diabetic market grew at 6.1 per cent and cardiac at 7.2 per cent in chronic business. Anti-malarials grew by 21.2 per cent, whereas derma market was at 15.2 per cent. Bonus in the anti-infective segment grew by 5.1 per cent, whereas in respiratory market it has seen 19.1 per cent growth.
|
Super Group
|
MAT Nov13
|
GR%
|
Mth Nov 13
|
GR%
|
| IPM |
72772
|
5.3
|
6291
|
6.9
|
| ANTI-INFECTIVES |
12505
|
1.1
|
1092
|
2.6
|
| CARDIAC |
8975
|
8.6
|
761
|
7.2
|
| GASTRO INTESTINAL |
8278
|
5.2
|
671
|
8.4
|
| VITAMINS/MINERALS/NUTRIENTS |
6402
|
4.1
|
527
|
6.2
|
| RESPIRATORY |
5646
|
6.7
|
592
|
15.1
|
| PAIN/ANALGESICS |
5239
|
3.5
|
452
|
5.4
|
| ANTI DIABETIC |
5031
|
9.2
|
432
|
6.1
|
| GYNAECOLOGICAL |
4650
|
3.5
|
372
|
3.1
|
| NEURO/CNS |
4551
|
8.4
|
383
|
5.1
|
| DERMA |
3938
|
8.7
|
363
|
15.2
|
| OPHTHAL/OTOLOGICALS |
1321
|
7.9
|
111
|
12.8
|
| HORMONES |
1242
|
5.9
|
107
|
2.0
|
| ANTI-NEOPLASTICS |
980
|
23.5
|
86
|
15.7
|
| OTHERS |
952
|
3.1
|
83
|
5.7
|
| BLOOD RELATED |
875
|
2.7
|
69
|
3.1
|
| VACCINES |
835
|
-3.3
|
63
|
-8.2
|
| ANTI MALARIALS |
598
|
-2.2
|
62
|
21.2
|
| SEX STIMULANTS/EJUVENATORS |
423
|
7.8
|
37
|
-3.2
|
| STOMATOLOGICALS |
331
|
7.3
|
28
|
12.5
|
From regional perspective Bihar has grown the highest at 16.6 per cent whereas Delhi has registered 16.4 per cent. Biggest region Tamil Nadu de-grew at 7.5 per cent and Andhra Pradesh rest de-grew at 5.2 per cent. Two regions have had negative growths in November 2013.
The biggest molecule Amoxycillin + Clavulanic grew by 9.7 per cent, whereas Cefixime grew at 2.3 per cent. Paracetamol grew at 5.1 per cent and Azithromycin grew by 2.7 per cent. The markets of Vitamin- D grew by 49.5 per cent, Glimepiride + Metformin grew at 40.8 per cent, Rosuvastain, Levocetirizine + Montelukast & Telmisartan by 22 per cent.
Amongst the top brands in the IPM, Phensedyl has shown 63 per cent growth, Glycomet-GP shows 62 per cent growth, Moxikind – CV at 33 per cent and Clavam at 29 per cent.
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocd.net